The closing price of Sanofi (NASDAQ: SNY) was $47.86 for the day, up 1.76% from the previous closing price of $47.03. In other words, the price has increased by $+0.83 from its previous closing price. On the day, 2219765 shares were traded. SNY stock price reached its highest trading level at $47.90 during the session, while it also had its lowest trading level at $47.33.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
Our analysis of SNY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.40. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
Valuation Measures:
As of this moment, Sanofi’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.59, and their Forward P/E ratio for the next fiscal year is 9.61. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52 while its Price-to-Book (P/B) ratio in mrq is 1.52.
Stock Price History:
Over the past 52 weeks, SNY has reached a high of $57.79, while it has fallen to a 52-week low of $36.91. The 50-Day Moving Average of the stock is 48.01, while the 200-Day Moving Average is calculated to be 46.07.
Shares Statistics:
SNY traded an average of 1.95M shares per day over the past three months and 1.37M shares per day over the past ten days. A total of 2.51B shares are outstanding, with a floating share count of 2.24B. Insiders hold about 16.40% of the company’s shares, while institutions hold 10.30% stake in the company. Shares short for SNY as of Jan 12, 2023 were 2.96M with a Short Ratio of 2.74M, compared to 2.84M on Dec 14, 2022.
Dividends & Splits
With its trailing 12-month dividend rate of 3.20, SNY has a forward annual dividend rate of 1.90. Against a Trailing Annual Dividend Yield of 6.80%, it implies a Forward Annual Dividend Yield of 3.72%. The stock’s 5-year Average Dividend Yield is 3.86.
Earnings Estimates
The firm’s stock currently is rated by 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was $1.09. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $4.75 and $4.31 for the fiscal current year, implying an average EPS of $4.52. EPS for the following year is $4.98, with 2 analysts recommending between $5.01 and $4.96.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $11.92B to a low estimate of $10.83B. As of the current estimate, Sanofi’s year-ago sales were $10.85B, an estimated increase of 4.40% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $11.17B, an increase of 3.70% less than the figure of $4.40% in the same quarter last year. There is a high estimate of $11.33B for the next quarter, whereas the lowest estimate is $10.91B.
A total of 4 analysts have provided revenue estimates for SNY’s current fiscal year. The highest revenue estimate was $50.05B, while the lowest revenue estimate was $46.94B, resulting in an average revenue estimate of $48.57B. In the same quarter a year ago, actual revenue was $45.17B, up 7.50% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $50.73B in the next fiscal year. The high estimate is $51.76B and the low estimate is $49.77B. The average revenue growth estimate for next year is up 4.40% from the average revenue estimate for this year.
